Physician profile
Ellen M Field
NPI 1407823297
$418,239.68
in general payments reported to CMS, 2019-2025
31 companies · $65K in 2025
The $65K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $53K · 2021: $49K · 2022: $47K · 2023: $35K · 2024: $55K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Travel and Lodging: $16K · Consulting Fee: $11K · Food and Beverage: $8,045 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,147.00 |
| Travel and Lodging | $16,264.77 |
| Consulting Fee | $11,045.00 |
| Food and Beverage | $8,044.80 |
| Education | $230.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137,852.65 | 2019-2025 | Evenity, Prolia, Enbrel |
| Lilly USA, LLC | $68,585.89 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $63,550.40 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Ucb, INC. | $44,549.22 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $41,694.23 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| United Rheumatology | $28,750.00 | 2019-2021 | |
| Abbvie INC. | $16,983.33 | 2019-2023 | Skyrizi, Rinvoq |
| Genentech USA, INC. | $12,376.53 | 2019-2023 | Actemra, Rituxan |
| Eli Lilly and Company | $774.99 | 2020-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $442.83 | 2019-2025 | |
| Pfizer INC. | $435.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $405.10 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $396.50 | 2019-2023 | Benlysta |
| Cumberland Pharmaceuticals, INC. | $339.74 | 2021-2023 | Reditrex |
| Celgene Corporation | $149.11 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.84 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $116.63 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $115.94 | 2020 | |
| Genzyme Corporation | $113.18 | 2021 | |
| Aurinia Pharma U.S., INC. | $104.45 | 2021-2022 | |
| Medexus Pharma, INC. | $78.50 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $75.47 | 2021-2022 | |
| Fidia Pharma USA INC. | $40.70 | 2023 | Hymovis |
| Sobi, INC | $37.36 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $26.49 | 2019 | |
| Horizon Therapeutics Plc | $25.09 | 2020-2022 | |
| Antares Pharma, INC. | $21.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.24 | 2019 | |
| Radius Health, INC. | $16.52 | 2019 | |
| Depuy Synthes Sales INC. | $16.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.